Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1967 1
1982 1
1997 2
1998 2
1999 1
2000 1
2006 3
2007 3
2008 1
2009 1
2010 2
2012 2
2013 2
2015 1
2016 1
2017 1
2018 2
2019 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Zander T, et al. Among authors: lerch e. Leukemia. 2023 Mar;37(3):699-701. doi: 10.1038/s41375-023-01809-z. Epub 2023 Jan 12. Leukemia. 2023. PMID: 36635391 Free PMC article. Clinical Trial. No abstract available.
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.
Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Gerber B, et al. Among authors: lerch e. Haematologica. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22. Haematologica. 2018. PMID: 29472358 Free PMC article. No abstract available.
["Epilepsia peruviana"].
Lerch E, Gössi B, Henzen C. Lerch E, et al. Schweiz Med Wochenschr. 1998 Oct 10;128(41):1559. Schweiz Med Wochenschr. 1998. PMID: 9816616 German. No abstract available.
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.
Samaras P, Bargetzi M, Betticher DC, Driessen C, Duchosal MA, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C. Samaras P, et al. Among authors: lerch e. Swiss Med Wkly. 2019 Apr 3;149:w20031. doi: 10.4414/smw.2019.20031. eCollection 2019 Mar 25. Swiss Med Wkly. 2019. PMID: 30943308 Free article.
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R, Manz MG, Pederiva S, Waibel C, Caspar C, Lerch E, Flammer AJ, Brouwers S, Seeger H, Heimgartner R, Fehr T, Rossi D, Bianchi E, Stüssi G, Ghilardi G, Gerber B. Schwotzer R, et al. Among authors: lerch e. Hematol Oncol. 2019 Dec;37(5):595-600. doi: 10.1002/hon.2677. Epub 2019 Nov 6. Hematol Oncol. 2019. PMID: 31486522
30 results